Elisa Gálvez Muñoz, Medical Director of Pivotal, shared on LinkedIn:
“Day 3 of ESMO 2026 is here, and we got an extra hour during last night to let Saturday’s results sink in.
Four phase 3 late-breakers in lung, gastro-oesophageal and biliary tract cancer at the Presidential Symposium II, proffered paper and rapid oral sessions will add LBA in NSCLC, rectal cancer, gastro-oesophageal cancer and skin tumours, including cutaneous squamous cell and Merkel cell carcinoma.
Also on our radar today, TTD Group – Grupo de Tratamiento de los Tumores Digestivos will be presenting additional data on CR-SEQUENCE trial on poster 862P, ‘Survival impact of hepatic metastasectomy during sequential systemic treatment in left-sided RAS wild-type metastatic colorectal cancer (mCRC)‘ (Hall 5). Pivotal is proud to have contributed to this work.
Which session is on your agenda?
Coffee loaded, notebooks open. Let’s go!”
You can also read: 25 Posts Not to Miss from ESMO Congress 2026: Day 3
